Nektar Therapeutics reports a Return on Equity (ROE) of -27.44%.

What is NKTR's dividend yield?

Nektar Therapeutics offers a dividend yield of 0.00%.

What is NKTR's Quality Score?

Our AI rates NKTR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NKTR?

Our AI Timing Score for NKTR is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NKTR belong to?

Nektar Therapeutics is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Nektar Therapeutics (NKTR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

NKTR AI Analysis Summary

Our AI summary for NKTR: Nektar Therapeutics (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -27.44%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NKTR

Nektar Therapeutics

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 72.76

2.17 (3.07%) Day Change

Watchlist Portfolio Compare Chart

0.04

D/E

-27.4%

ROE

-20.7%

ROA

0.00%

Div Yield

NEKTAR THERAPEUTICS
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 72.76 Price 2.17 (3.07%) Day Change	NEWS SCORE: N/A

NKTR, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	72.76
PBV / Sector	4.14 / 44,022.72
Earning Per Share	-4.82

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	50.14 M
Average 1W Daily Value	48.90 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-284.18 / 98.24
NPM Average (%) / Sector	-281.68 / -1,697.63
NPM Change Average (%) / Sector	14.37 / 5,097.97 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-20.71 / 185,260.96
ROA Average (%) / Sector	-47.91 / 36,684.70
ROA Change Average (%) / Sector	-6.21 / 422,221.66
ROE (%) / Sector	-27.44 / 243,762.23
ROE Average (%) / Sector	-143.42 / 48,758.47
ROE Change Average (%) / Sector	2.77 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:35
Symbol	NKTR
Name	NEKTAR THERAPEUTICS
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	33.79 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,384.96 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158

Phone: 415 482 5300

Website: https://www.nektar.com

Employees: 63

Sector: Healthcare >> Biotechnology

Description: Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.